Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

The global Enzyme Replacement Therapy (ERT) market is poised for significant expansion, projected to reach USD 21.62 billion ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

Health care companies recouped some of their recent losses amid generally strong earnings and deal activity. British drug maker AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its ...

The pharmaceutical company is accelerating its expansion in the country as President Donald Trump considers tariffs of up to ...

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid US leader ...